Archive for the 'NIH funding' category

Thought of the Day

Jul 24 2014 Published by under Careerism, NIH, NIH Careerism, NIH funding

What fraction of the stuff proposed in funded grants actually gets done after feasibility and field movement come to play?

22 responses so far

Sex differences in K99/R00 awardees from my favorite ICs

Jul 21 2014 Published by under Grantsmanship, NIH, NIH Careerism, NIH funding, Peer Review

Datahound has some very interesting analyses up regarding NIH-wide sex differences in the success of the K99/R00 program.

Of the 218 men with K99 awards, 201 (or 92%) went on to activate the R00 portion. Of the 142 women, 127 (or 89%) went on to these R00 phase. These differences in these percentages are not statistically different.

Of the 201 men with R00 awards, 114 (57%) have gone on to receive at least 1 R01 award to date. In contrast, of the 127 women with R00 awards, only 53 (42%) have received an R01 award. This difference is jarring and is statistically significant (P value=0.009).

Yowza.

So per my usual, I'm very interested in what the ICs that are closest to my lab's heart have been up to with this program. Looking at K99 awardees from 07 to 09 I find women PIs to constitute 3/3, 1/3 and 2/4 in one Institute and 1/7, 2/6 and 5/14 in the other Institute. One of these is doing better than the other and I will just note that was before the arrival of a Director who has been very vocal about sex discrimination in science and academia.

In terms of the conversion to R01 funding that is the subject of Datahound's post, the smaller Institution has decent outcomes* for K99 awardees from 07 (R01, R21, nothing), 08 (R01, R01, R01) and 09 (P20 component, U component, nothing, nothing).

In the other Institute, the single woman from 07 did not appear to convert to the R00 phase but Google suggests made Assistant Professor rank anyway. No additional NIH funding. The rest of the 07 class contains 4 with R01 and two with nothing. In 08, the women PIs are split (one R01, one nothing) similar to the men (2 R01, 2 with nothing). In 09 the women PIs have two with R01s, one R03 and two with nothing.

So from this qualitative look, nothing is out of step with Datahound's NIH-wide stats. There are 14/37 women PIs, this 38% is similar to the NIH-wide 39% Datahound quoted although there may be a difference between these two ICS (30% vs 60%) that could stand some inquiry. One of 37 K99 awardees failed to convert to R00 from the K99 (but seems to be faculty anyway). Grant conversion past the R00 is looking to be roughly half or a bit better.

I didn't do the men for the 2009 cohort in the larger Institute but otherwise the sex differences in terms of getting/not getting additional funding beyond the R00 seems pretty similar.

I do hope Datahound's stats open some eyes at the NIH, however. Sure, there are reasons to potentially excuse away a sex difference in the rates of landing additional research funding past the R00. But I am reminded of a graph Sally Rockey posted regarding the success rate on R01-equivalent awards. It showed that men and women PIs had nearly identical success rates on new (Type 1) proposals but slightly lower success on Renewal (Type 2) applications. This pastes over the rates of conversion to R00 and the acquisition of additional funding, if you squint a bit.

Are women overall less productive once they've landed some initial funding? Are they viewed negatively on the continuation of a project but not on the initiation of it? Are women too humble about what they have accomplished?
__
*I'm counting components of P or U mechanisms but not pilot awards.

15 responses so far

Strategies for your #A2asA0 Resubmissions

Jun 30 2014 Published by under Ask DrugMonkey, NIH, NIH Careerism, NIH funding

A query came into the blog email box about how to deal with submitting a new grant based on the prior A1 that did not get funded. As you know, NIH banned any additional revisions past the A1 stage back in 2009. Recently, they have decided to stop scrutinizing "new" applications for similarity with previously reviewed and not-funded applications. This is all well and good but how should we go about constructing the "new" grant, eh? A query from a Reader:

Do you use part of your background section to address reviewer comments? You're not allowed to have an introduction to the application, but as far as I can tell there is no prohibition on using other parts of the application as a response to reviewers.

I could see the study section as viewing this a) innovative, b) a sneaky attempt to get around the rules, c) both a and b.

I am uncertain about the phrasing of the Notice where it says "must not contain an introduction to respond to the critiques from the previous review". In context I certainly read this as prohibiting the extra page that you get for an amended application. What is less clear is whether this is prohibiting anything that amounts to such introduction if you place it in the Research Strategy. I suspect you could probably get away with direct quotes of reviewer criticisms.

This seems unwise to me, however. I think you should simply take the criticisms and revise your proposal accordingly as you would in the case of an amended version. These revisions will be sprinkled throughout the application as appropriate- maybe a change in the Significance argument, maybe a new Experiment in Aim 2, maybe a more elaborated discussion of Potential Pitfalls and Alternative Approaches.

Given the comments, perhaps you might need to state some things twice or set off key points in bold type. Just so the next set of reviewers don't miss your point.

But I see no profit in directly quoting the prior review and it just wastes space.

10 responses so far

Quality of grant review

Jun 13 2014 Published by under Grant Review, NIH funding, Peer Review

Where are all the outraged complaints about the quality of grant peer review and Errors Of Fact for grants that were scored within the payline?

I mean, if the problem is with bad review it should plague the top scoring applications as much as the rest of the distribution. Right?

47 responses so far

Impressions of the "no-cost extension" of your NIH grant.

Jun 02 2014 Published by under NIH, NIH Careerism, NIH funding

It has recently come to my attention that not everyone views the no-cost extension (NCE) of a NIH grant the same way I do.

When the interval of support is over for many of the NIH grant mechanisms, the PI (actually the University or Institute, of course) can request a NCE. This means that while the NIH is not going to give out any additional money past the original award, the University may continue to spend any un-expended funds. My experience has been that NCE requests, particularly the first year, are approved by default.

I am pretty sure that you are supposed to follow the usual rules for rolling money from one funded interval to the next funded interval, i.e., it is supposed to be only 25% of the prior year or less. Also, if you have a great excuse for why you have slightly more than 25% left over I would think this would not be a huge problem.

Personally, I have requested a NCE essentially by default for every grant award that permits it and assuming that the competing renewal has not been approved in time to keep the funded intervals rolling.

There are my own local institutional reasons for doing so, mostly having to do with moderate red tape factors.

I thought that it was sort of required in order to submit a competing continuation (now called "renewal") application. I have one grants management assurance that this is not the case but I would still want to check up on how that works. After all, with the new A2 as A0 rules, can't we just submit a competing continuation application for a grant which has been unfunded for 5 years? 10 years? Wait....google...google....NIAID says:

Is there a window of time that a PI can submit an application as a renewal? Must the original grant still be active?

No. The grant need not be active and there is no time limit for a renewal application. However, reviewers will probably be concerned by major gaps.

If a significant amount of time has elapsed, indicate what you have done in the interim. Highlight any preliminary data you may have obtained, and show that your planned research is current with the latest science.

OK, maybe I learned something this year. I mean, I'm sure I have read that before about renewals but somehow it never really connected up.

Also, for some reason maybe I thought that reviewers would be more confident that you were actively working on the project past the end date if you could say it was in NCE.

My question for the peanut gallery today is, how seriously do you take the NCE when you see it mentioned in a Biosketch or elsewhere in the grant proposal? Is it just meaningless...as in "of course they applied for a NCE, duh" or below notice altogether? Does apply only when it is a competing continuation / renewal of the grant which is in NCE?

In a related vein, does it "count" as current research funding? Do you see a grant in NCE and mentally chalk it up under the PI or other Key Personnel's "funded grants"? In the Biosketch does it go under "completed" or "ongoing" Research Support?

Do you assume it might be pending renewal if it is not the prior interval of the grant you are reviewing now?

19 responses so far

NIH takes their Sex-Differences show on the road

May 21 2014 Published by under Diversity in Science, NIH, NIH Careerism, NIH funding

In my view, once it is on The News Hour then it is really news.

Nature published a commentary by NIH Director Francis S. Collins and NIH Office of Research on Women's Health Director Janine A. Clayton which warns us that the NIH will start insisting on the inclusion of more sex-difference comparisons. These are to extend from cells to animal models across many areas of pre-clinical work.

The NIH is now developing policies that require applicants to report their plans for the balance of male and female cells and animals in preclinical studies in all future applications, unless sex-specific inclusion is unwarranted, based on rigorously defined exceptions. These policies will be rolled out in phases beginning in October 2014, with parallel changes in review activities and requirements.

I cannot wait to see what the "rigorously defined exceptions" will be for several types of research in which I have an interest. Every rat self-admin study must now include both males and females? For all treatment conditions or will it be acceptable to just tack the sex-comparison on at the end?

Furthermore, the NIH will monitor compliance of sex and gender inclusion in preclinical research funded by the agency through data-mining techniques that are currently being developed and implemented. Importantly, because the NIH cannot directly control the publication of sex and gender analyses performed in NIH-funded research, we will continue to partner with publishers to promote the publication of such research results.

oooooh. "partner with publishers" eh? Of course this is because Clayton and Collins realize that higher JIF journals are entirely uninterested in things as pedestrian as sex-comparisons, particularly when the outcome of the study is "no difference". Which, btw, is one of the reasons nobody* wants to waste their precious time and grant money doing something as low-return as sex-comparisons. So somehow the NIH is going to lean on publishers to be...friendlier....to such work. I do hope they realize that this is not going to work. The contingencies are not going to change because the NIH asks. Now, if they actually went all in and dismantled GlamourMagScience culture by the judicious use of grant award, grant auditing and rules about the ratio of publications to effort expended... then we might see some progress. That will never happen and thus there will be no change in the publication contingencies that fight against sex-comparison studies.

Dr. Clayton went on The News Hour where Judy Woodruff asked her (and Phyllis Greenberger of Society for Women's Health Research) some pretty obvious questions. Woodruff wanted to know if there were any clear examples in which women were put at risk or their health suffered because of a lack of such research. She also wanted to know what the implications for research might be- would it be more difficult or more expensive. Finally, Woodruff asked if scientists would resist.

From the transcript:

JUDY WOODRUFF: But how hard is that? Does that mean — is it extra work, is it more expensive? What’s involved in making sure there’s a gender balance?

Now Greenberger snuck in a "Both" off camera but then Clayton went on to be ridiculous and fail to answer the question. The answer is indeed "both" and it is a serious one if the NIH expects to get results. It will be more expensive, progress will be slower and it will be "harder" in the sense of teasing out the right experimental designs and variables so that an interpretable result can be reached. It isn't rocket science, exactly, but it is harder.

JUDY WOODRUFF: Phyllis Greenberger, were there — were there actually individuals who were harmed or where help wasn’t delivered because the research was done only on males?

Greenberger totally walked around this one and Woodruff, to her credit, fronted Clayton with the same question a bit later. Clayton referred to heart attack warning symptoms in women that might differ from men...of course this has nothing whatever to do with preclinical research. Gaaah! So frustrating. Greenberger chimed back in with talk of drugs being removed from the market for adverse effects in women....with no indication that these were adverse effects that would have been identified in female-specific PREclinical research. C'mon NIH! If you are going to take a run at this, please prepare your argument!


JUDY WOODRUFF: And is that the reason that it wasn’t done earlier, Dr. Clayton, that there was just pushback in the scientific community?

The answer is illustrative of the problem at the NIH....

DR. JANINE CLAYTON: It’s hard to say. There are probably a lot of factors that are involved.

And what’s really important now is right now we have been able to put the focus on getting this as a priority. As Phyllis mentioned, the Society and other advocacy groups and scientists and others have talked about this in the past. In fact, we are supporting scientists who are doing this research, but it wasn’t enough of a priority. In some way, it was like a blind spot. Scientists weren’t thinking about it.

Yes, there are a lot of factors. They aren't all that complicated either, since they boil down to scientists who want to conduct sex-differences comparisons being able to win funding to do the work.

Clayton is right. The NIH does indeed support investigators doing sex-differences studies.Those scientists do not have a problem of "priority" from the perspective of their own intrinsic motivation.

PubMedSexDiffsWith respect to whether scientists resist, I enjoin you to go over to PubMed and type in Sex Differences and see what fill-in choices are offered to you. Click on several of these searches and see what you find. You will find funded projects in many of your favorite domains of interest. If you bother to click on the papers and look at the grant attributions, you may even find that many of these investigations were completed under NIH funding!

So when Clayton (and in the Commentary she is joined by Director Collins) claims it isn't a "priority", it seems misplaced to put this on the shoulders of extramural scientists.

If the NIH wants more sex-differences studies then they need to deploy their tastiest carrot to greater effect. Put out some Funding Opportunity Announcements and see what happens! Fund a few Supplements to the people who are already doing sex-comparisons! Pick up a few grants that missed the payline...again, from the people who are already proposing sex-comparisons!

And if you want to lure in new converts that you didn't get with an RFA or a Program Announcement? This is simple. Just put out a policy that any grant application with a credible stab at a sex-comparison component gets an extra 5 percentile points credit towards the payline for funding.

Just you wait and see how many sudden converts you make!

___
*of the GlamourMag class investigator

20 responses so far

Revision strategy, with an eye to the new A2 as A0 policy at NIH

Occasionally, Dear Reader, one or another of you solicits my specific advice on some NIH grant situation you are experiencing. Sometimes the issues are too specific to be of much general good but this one is at least grist for discussion of how to proceed.

Today's discussion starts with the criterion scores for an R01/equivalent proposal. As a reminder, the five criteria are ordered as Significance, Investigator, Innovation, Approach and Environment. The first round for this proposal ended up with

Reviewer #1: 1, 1, 1, 3, 1
Reviewer #2: 3, 1, 1, 3, 1
Reviewer #3: 6, 2, 1, 8, 1
Reviewer #4: 2, 1, 3, 2, 1

From this, the overall outcome was.... Not Discussed. Aka, triaged.

As you might imagine, the PI was fuming. To put it mildly. Three pretty decent looking reviews and one really, really unfavorable one. This should, in my opinion, have been pulled up for discussion to resolve the differences of opinion. It was not. That indicates that the three favorable reviewers were either somehow convinced by what Reviewer #3 wrote that they had been too lenient...or they were simply not convinced discussion would make a material difference (i.e. push it over the "fund" line). The two 3s on Approach from the first two reviewers are basically a "I'd like to see this come back, fixed" type of position. So they might have decided, screw it, let this one come back and we'll fight over it then.

This right here points to my problem with the endless queue of the revision traffic pattern and the new A2 as A0 policy that will restore it to the former glory. It should be almost obligatory to discuss significantly divergent scores, particularly when they make a categorical difference. The difference between triaged and discussed and the difference between a maybe-fundable and a clearly-not-fundable score is known to the Chair and the SRO of the study section. Thee Chair could insist on resolving these types of situations. I think they should be obliged to do so, personally. It would save some hassle and extra rounds of re-review. It seems particularly called-for when the majority of the scores are in the better direction because that should be some minor indication that the revised version would have a good chance to improve in the minds of the reviewers.

There is one interesting instructive point that reinforces one of my usual soapboxes. This PI had actually asked me before the review, when the study section roster was posted, what to do about reviewer conflicts. This person was absolutely incensed (and depressed) about the fact that a scientific competitor in highly direct competition with the proposal had been brought on board. There is very little you can do, btw, 30 days out from review. That ship has sailed.

After seeing the summary statement, the PI had to admit that going by the actual criticism comments, the only person with the directly-competing expertise was not Reviewer #3. Since the other three scores were actually pretty good, we can see that I am right on the assumption of what a reviewer will think of your application based on perceptions of competition or personal dis/like. You will often be surprised that the reviewer that you assume is out to screw your application over will be pulling for it. Or at least, will be giving it a score that is in line with the majority of the other reviewers. This appears to be what happened in this case.

Okay. So, as I may have mentioned I have been reluctantly persuading myself that revising triaged applications is a waste of time. Too few of them make it over the line to fund. And in the recently past era of A1 and out....well perhaps time was better spent on a new app. In this case, however, I think there is a strong case for revision. Three of four (and we need to wonder about why there even were four reviews instead of three) of these criterion score sets look to me like scores that would get an app discussed. The ND seems to be a bit of an unfair result, based on the one hater. The PI agreed, apparently, and resubmitted a revised application. In this case the criterion scores were:

Reviewer #1: 1, 2, 2, 5, 1
Reviewer #2: 2, 2, 2, 2, 1
Reviewer #3: 1, 1, 2, 2, 1
Reviewer #4: 2, 1, 1, 2, 1
Reviewer #5: 1, 1, 4, 7, 1

I remind you that we cannot assume any overlap in reviewers nor any identity of reviewer number in the case of re-assigned reviewers. In this case the grant was discussed at study section and ended up with a 26 voted impact score. The PI noted that a second direct competitor on the science had been included on the review panel this time in addition to the aforementioned first person in direct competition.

Oh Brother.

I assure you, Dear Reader, that I understand the pain of getting reviews like this. Three reviewers throwing 1s and 2s is not only a "surely discussed" outcome but is a "probably funded" zone, especially for a revised application. Even the one "5" from Reviewer #1 on Approach is something that perhaps the other reviewers might talk him/her down from. But to have two obviously triage numbers thrown on Approach? A maddening split decision, leading to a score that is most decidedly on the bubble for funding.

My seat of the pants estimation is that this may require Program intervention to fund. I don't know for sure, I'm not familiar with the relevant paylines and likely success rates for this IC for this fiscal year.

Now, if this doesn't end up winning funding, I think the PI most certainly has to take advantage of the new A2 as A0 policy and put this sucker right back in. To the same study section. Addressing whatever complaints were associated with Reviewer #1's and #5's criticisms of course. But you have to throw yourself on the mercy of the three "good" reviewers and anyone they happened to convince during discussion. I bet a handful of them will be sufficient to bring the next "A0" of this application to a fundable score even if the two less-favorable reviewers refuse to budge. I also bet there is a decent chance the SRO will see that last reviewer as a significant outlier and not assign the grant to that person again.

I wish this PI my best of luck in getting the award.

29 responses so far

The NIH says investigators must incorporate sex-differences analyses in their studies

May 14 2014 Published by under Drug Abuse Science, NIH, NIH funding, Sex Differences

For some reason I am having a DOI error on the actual comment from Clayton and Collins. So until that is resolved, the sourcing is from the journalists who got the embargoed version.

Apparently Janine Clayton and Francis Collins have issued a commentary on a new policy that the NYT describes as:

The N.I.H. is directing scientists to perform their experiments with both female and male animals and include both sexes in sufficient numbers to see statistically significant differences. Grant reviewers will be instructed to take the sex balance of each study design into account when awarding grants.

Yeah, that sounds pretty clear. My studies just doubled...which means really that they were just cut in half. I'm cool with that. I actually agree that it would be good if we did almost everything as a sex-differences study.

There's the money though. Sex difference studies in a behaving animal are not just a doubling as it happens (and as I inaccurately described it just above). From a prior post on this topic entitled: The funding is the science II, "Why do they always drop the females?"

As nicely detailed in Isis' post, the inclusion of a sex comparison doubles the groups right off the bat but even more to the point, it requires the inclusion of various hormonal cycling considerations. This can be as simple as requiring female subjects to be assessed at multiple points of an estrous cycle. It can be considerably more complicated, often requiring gonadectomy (at various developmental timepoints) and hormonal replacement (with dose-response designs, please) including all of the appropriate control groups / observations. Novel hormonal antagonists? Whoops, the model is not "well established" and needs to be "compared to the standard gonadectomy models", LOL >sigh<.

The money and the progress.

Keep in mind, if you will, that there is always a more fundamental comparison or question at the root of the project, such as "does this drug compound ameliorate cocaine addiction?" So all the gender comparisons, designs and groups need to be multiplied against the cocaine addiction/treatment conditions. Suppose it is one of those cocaine models that requires a month or more of training per group? Who is going to run all those animals ? How many operant boxes / hours are available? and at what cost?

Oh, don't worry bench jockeys. According to the NYT article:

Researchers who work with cell cultures are also being encouraged to study cells derived from females as well as males, and to do separate analyses to tease out sex differences at the cellular level.

“Every cell has a sex,” Dr. Clayton said in a telephone interview. “Each cell is either male or female, and that genetic difference results in different biochemical processes within those cells.”

“If you don’t know that and put all of the cells together, you’re missing out, and you may also be misinterpreting your data,” Dr. Clayton added. For example, researchers recently discovered that neurons cultured from males are more susceptible to death from starvation than those from females, because differences in the ways their cells process nutrients.

"Encouraged". Okay, maybe you CultureClowns have an escape clause here. Animal model folks are facing "demanded" language.

Final observations are ridiculous:

But [the new policies] are likely to be met with resistance from scientists who fear increased costs and difficulty in performing their experiments. Studying animals of both sexes may potentially double the number required in order to get significant results.

“There’s incredible inertia among people when it comes to change, and the vast majority of people doing biological research are going to think this is a huge inconvenience,” Dr. Zucker said.

...

Margaret McCarthy, a neuroscientist at University of Maryland School of Medicine who studies sex differences, agreed. “The reactions will range from hostile — ‘You can’t make me do that’ — to ‘Oh, I don’t want to control for the estrous cycle,'” she said.

This has nothing to do with whether a scientist "wants" to or not.

Let me be clear, I want to do sex-differences studies. I am delighted that this will be a new prescription. I agree with the motivating sentiments.

What I "fear" is that grant applications will be kicked in the teeth if they include sex differences comparisons. What I "fear" is that my research programs will be even less productive on the main area of interest, to the tune of a lot of extra work that will simply confirm a lot of what we already know. For example, female rats tend to self-administer more drug than males do. A lot of my colleagues have been working on these topics for a long time. The identification of those areas where it actually matters (i.e., sex difference effects that haven't yet been detected) are going to come along with a lot of negative findings. What I "fear" is that when we are interested in a certain thing, there is a bit of sex-differences literature and the hypothesis is going to be "males and females are the same" or even "females are more/less sensitive to drug" that this is going to bring down the holy hells of reviewer wrath over what hypothesis we are testing.

I fear a lot of things about this. What I don't fear is my own interest in the topic. What I don't fear is the "inconvenience". I don't even fear "difficulty". It just isn't that difficult to add female groups to my studies.

What it takes is additional grant funding. Or tolerance on the part of P&T committees, hiring committees and grant review panels for apparently reduced progress on a scientific topic of interest. And those things are not at all easy to come by.

The funny thing is, we've been taking steps in the lab toward this direction in the past year anyway. So I should be grateful I have at least that little tiny bit of a head start on this stuff.

22 responses so far

Grantome details the trajectories of the NIH Grant "have" institutions

This is a fascinating read.

Grantome.com is a project of data scientists who have generated a database of grant funding information. This particular blog post focuses on a longitudinal analysis of some of the most heavily NIH-funded Universities and other research institutions. It shows those which are maintaining stable levels of support, those in decline and those which are grabbing an increased share of the extramural NIH pie.

The following graph was described thusly:

Each histogram bar represents the range in the percentage of grants that has been held between 1986 and 2013. The current, 2013 level is represented by a black vertical line. Finally, arrows inform on the latest trend in how these values are changing, where their length and direction reflect predictions in the level of funding that each institution will have over the next 3 years. These predictions were made from linear extrapolation of the average rate of change that was observed over the last 3 years.

This serves as an interesting counterpoint to the discussion of the "real problem" at the NIH as it has typically centered around too many awards per PI, too much funding per PI, the existence of soft-money job categories, the overhead rates enjoyed by certain Universities, etc.

I am particularly fascinated by their searchable database, in which you can play around with the funding histories of various institutions. Searches by fiscal year, funding IC are illuminating, as is toggling between total costs and the number of awards on the graphical display.

23 responses so far

Your Grant in Review: The Biosketch Research Support Section

Apr 21 2014 Published by under Grant Review, Grantsmanship, NIH, NIH funding

A question came up on the twitts about the Research Support section of the NIH Biosketch.

The answer is that no, you do not. I will note that I am not entirely sure if this changed over the years or if my understanding of this rule was incomplete at the start. However, the instructions on the Sample Biosketch [PDF] provided by the NIH are clear.

D. Research Support
List both selected ongoing and completed research projects for the past three years (Federal or non-Federally-supported). Begin with the projects that are most relevant to the research proposed in the application. Briefly indicate the overall goals of the projects and responsibilities of the key person identified on the Biographical Sketch. Do not include number of person months or direct costs.

The last bit is the key bit for Dr24Hour's question but I include the full description for a reason.

dr24Hours also asked:

and there was a followup to my initial negative response

Together, these questions seem to indicate a misunderstanding of what this section is for, and what it is trying to communicate.

Note the use of the term "selected" and "most relevant" in the above passage.

The Biosketch is, in total, devoted to convincing the reviewers that the PI and other Investigative staff have the chops to pull off the project under review. It is about bragging on how accomplished they all are. Technically, it is not even a full recitation of all the support one has secured in the past three years. This is similar to how the Peer-reviewed Publications section is limited to 15 items, regardless of how many total publications that you have.

Inclusion of items in the Research Support section is to show that the Investigators have run projects of similar scope with acceptable success. Yes, the definition of acceptable success is variable, but this concept is clear. The goal is to show off the Investigator's accomplishments to the best possible advantage.

The Research Support is not about demonstrating that the PI is successful at winning grants. It is not about demonstrating how big and well-funded the lab has been (no direct costs). It is not even about the reviewers trying to decide if the PI is spread too thinly (no listing of effort). This is not the point*.

In theory, one would just put forward a subset of the best elements on one's CV. The most relevant and most successful grant awards. If space is an issue (the Biosketch is limited to 4 pages) then the PI might have to make some selections. Obviously you'd want to start with NIH R01s (or equivalent) if the application is an R01. Presumably you would want to supply the reviewer with what you think are your most successful projects- in terms of papers, scientific advance, pizzaz of findings or whatever floats your boat.

You might also want to "selectively" omit any of your less-successful awards or even ones that seem like they have too much overlap with the present proposal.

Don't do this.

If it is an NIH award, you can be assured at least one of the reviewers will have looked you up on RePORTER and will notice the omission. If it is a non-NIH award, perhaps the odds are lower but you just never know. If the reviewer thinks you are hiding something...this is not good. If your award has been active in the past three years and is listed somewhere Internet-accessible, particularly on your University or lab website, then list it on the Biosketch.

Obviously this latter advice only applies to people who have a lot of different sources of support. The more of them you have, the tighter the space. Clearly, you are going to have to make some choices if your lab operates on a lot of different sources of support. Prioritize by what makes sense to you, sure, but make sure you pay attention to the communication you are trying to accomplish when making your selections. And beware of being viewed with a suspicion that you are trying to conceal something.
__
*Yes, in theory. I grasp that there will be reviewers using this information to argue that the PI is spread too thinly or has "too much" grant support.

10 responses so far

« Newer posts Older posts »